CD274 and esophageal squamous cell carcinoma: In conclusion, this is the first economic analysis of the addition of serplulimab to chemotherapy as a first-line treatment for PD-L1-positive patients with advanced ESCC using a Markov model, which presents evidence that can inform the development of relevant medical insurance policies and clinical decision-making.